Evidence map›Paper›PMID 35361287›Full record

ArticleBioelectronic medicine2022

Electrical neurostimulation in glaucoma with progressive vision loss.

Carl Erb, Sophie Eckert, Pia Gindorf, Martin Köhler, Thomas Köhler, Lukas Neuhann, Thomas Neuhann, Nadja Salzmann, Stefanie Schmickler, Jens Ellrich

Open access · goldAbstract read
In one paragraph

Article in Bioelectronic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. New Devices in Glaucoma.Ophthalmology and therapy · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Carl ErbAugenklinik Wittenbergplatz, Berlin, Germany.
Sophie EckertMedizentrum Eckert, Neu-Ulm, Germany.
Pia GindorfAugenklinik Wittenbergplatz, Berlin, Germany.
Martin KöhlerGemeinschaftspraxis Salzmann/Köhler, Hannover, Germany.
Thomas KöhlerGemeinschaftspraxis Salzmann/Köhler, Hannover, Germany.
Lukas NeuhannMVZ Prof. Neuhann GmbH, Munich, Germany.
Thomas NeuhannMVZ Prof. Neuhann GmbH, Munich, Germany.
Nadja SalzmannGemeinschaftspraxis Salzmann/Köhler, Hannover, Germany.
Stefanie SchmicklerAugen-Zentrum-Nordwest, Ahaus, Germany.
Jens EllrichMedical Faculty, Friedrich-Alexander-University, D-91052, Erlangen, Germany. jens.ellrich@fau.de.ORCID http://orcid.org/0000-0001-8033-4921
Medizinisches Versorgungszentrum Prof. Mathey, Prof. Schofer · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe retrospective study provides real-world evidence for long-term clinical efficacy of electrical optic nerve stimulation (ONS) in glaucoma with progressive vision loss.

methodsSeventy glaucoma patients (45 to 86 y) with progressive vision loss despite therapeutic reduction of intraocular pressure (IOP) underwent electrical ONS. Closed eyes were separately stimulated by bipolar rectangular pulses with stimulus intensities up to 1.2 mA sufficient to provoke phosphenes. Ten daily stimulation sessions within 2 weeks lasted about 80 min each. Right before ONS at baseline (PRE), vision loss was documented by static threshold perimetry and compared to the same assessment approximately 1 year afterwards (POST). Mean defect (MD) was defined as primary outcome parameter. Perimetries with a reliability factor (RF) of max. 20% were considered.

resultsPerimetry follow-up of 101 eyes in 70 patients fulfilled the criterion of a max. 20% RF. Follow-up was performed on average 362.2 days after ONS. MD significantly decreased from PRE 14.0 dB (median) to POST 13.4 dB (p < 0.01). 64 eyes in 49 patients showed constant or reduced MD as compared to baseline (PRE 13.4 dB vs. POST 11.2 dB). In 37 eyes of 30 patients, MD increased from PRE 14.9 dB to POST 15.6 dB.

conclusionsInnovative treatments that preserve visual function through mechanisms other than lowering IOP are required for glaucoma with progressive vision loss. The present long-term data document progression halt in more than 63% of affected eyes after ONS and, thus, extend existing evidence from clinical trials.

Indexed as

NeuromodulationNeuroprotectionOptic nervePerimetryRestoration

Identifiers

PMID35361287
PMCPMC8969331
OpenAlexW4220942219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.